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Statins have cholesterol-independent effects including an increased vascular nitric oxide activity and are commonly
used by patients with cardiovascular disease. Such patients frequently have cardiovascular diseases, which may be
treated with cilostazol, a platelet aggregation inhibitor. This study was designed to investigate whether combined use
of cilostazol would increase the inhibitory effect of statin on vascular smooth muscle and how maturation would
affect these responses. Female Wistar rats, aged 3–4 months (young) and 14–15 months (adult), were sacriﬁced by
cervical dislocation and the thoracic aorta was dissected and cut into 3- to 4-mm-long rings. The rings were mounted
under a resting tension of 1 g in a 20-ml organ bath ﬁlled with Krebs–Henseleit solution. Rings were precontracted
with phenylephrine (10−6 M), and the presence of endothelium was conﬁrmed with acetylcholine (10−6 M). Then, the
concentration–response curves were obtained for atorvastatin alone (10−10 to 3 × 10−4 M; control) and in the
presence of cilostazol (10−6 M) in young and adult rat aortas. This experimental protocol was also carried out in aorta
rings, which had been pretreated with NG-nitro-L-arginine methyl ester (L-NAME, 10−4 M). Atorvastatin induced
concentration-dependent relaxations in young and adult rat thoracic aorta rings precontracted with phenylephrine.
The pIC50 value of atorvastatin was signiﬁcantly decreased in adult rat aortas. In addition, pretreatment of aortas with
cilostazol enhanced the potency of atorvastatin in both young and adult aortas. Incubation with L-NAME did not
completely eliminate the relaxations to atorvastatin in the presence of cilostazol. These results suggest that combined
application of cilostazol with atorvastatin was signiﬁcantly more potent than atorvastatin alone. Combined drug
therapy may be efﬁcacious in delaying the occurrence of cardiovascular events.
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Introduction
Statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, have been broadly
used in clinical practice owing to both its potent lipid-modifying effects and other cardi-
oprotective effects including increasing nitric oxide production, improving inﬂammation and
oxidation, enhancing endothelial progenitor cells migration, and so on which now are
referred to as pleiotropic effects (4, 5, 28). Statins are widely used and are the most effective
hypolipidemic agents available for the reduction of cardiovascular risks and prevention of the
worsening of disease/disability in patients with established cardiovascular disease (secondary
prevention). Statins have cholesterol-independent effects including an increased vascular
nitric oxide activity and are commonly used by patients with cardiovascular disease. Such
patients frequently have cardiovascular diseases, which are treated with cilostazol, a platelet
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aggregation inhibitor. However, to the best of our knowledge, there are no studies that
analyze the combined effects of atorvastatin and cilostazol on vascular smooth muscle
reactivity.
Maturation and senescence are physiological process. The effects of biological age on
the responsiveness of the vascular system have been widely studied in terms of both
maturation and senescence. Despite numerous recent studies have aimed to determine the
effects of age on vascular reactivity of different agents, studies with statins remain incomplete
and there are no in vitro studies that analyze the effects of statins on age-dependent responses
of the rat aorta. Gong et al. (9) reported that the long-term administration of atorvastatin
improves age-related endothelial dysfunction in aged rat aorta. Furthermore, Alvarez de
Sotomayor et al. (2) have demonstrated that oral administration of simvastatin improves
endothelial dysfunction in the aorta from aged rats by mechanisms associated with enhanced
nitric oxide vasodilatation, reduced release of thromboxane A2 from cyclooxygenase, and
increased antioxidant properties of the vessel wall. These data underscore a new therapeutic
perspective for simvastatin in age-related endothelial dysfunction. These results are all
obtained in models, which used oral administration of statins.
Since its discovery in the 1980s, nitric oxide is in fact the elusive endothelium-derived
relaxing factor, it has become evident that nitric oxide is not only a major cardiovascular
signaling molecule, but changes in its bioavailability are crucial in the development of
atherosclerosis. Sustained high levels of harmful circulating stimuli associated with cardio-
vascular risk factors elicit responses in endothelial cells that appear sequentially, namely
endothelial cell activation and endothelial dysfunction. Endothelial dysfunction, character-
ized by reduced nitric oxide bioavailability, is now recognized by many as an early, reversible
precursor of atherosclerosis. It is known that the ability of the endothelium to produce nitric
oxide is reduced with aging (29).
Cilostazol, used as a selective inhibitor of type III phosphodiesterase (PDE3),
induces an antiplatelet and antithrombotic effect by increasing cyclic adenosine mono-
phosphate (cAMP) in platelets and vascular smooth muscle (15). Recently, Li et al. (17)
reported that cilostazol induced the relaxation of rabbit thoracic aorta through activation
of the big-conductance Ca2+-activated K+ channel via an endothelium-independent,
protein kinase A-dependent signaling pathway. No previous study has focused on the
effect of aging on the vasodilator effects of atorvastatin and also possible interaction of
cilostazol with statins in vitro. However, an interaction could result from the fact that both
drugs activate the nitric oxide–cyclic guanosine monophosphate pathway, thereby
producing vasodilation. This study was designed to determine the effect of age on the
statin-induced relaxation of rat thoracic aorta, and to identify whether pretreatment with
cilostazol affects the vascular reactivity to atorvastatin. We also examined the role of
nitric oxide in this interaction.
Materials and Methods
Animals and husbandry
Female Wistar rats, aged 3–4 months (young) and 14–15 months (adult), were obtained from
Application and Research Center of Experimental Medicine, Necmettin Erbakan University
(Konya, Turkey). The protocols of the animal experiments were approved by the internal
ethical committee of Application and Research Center of Experimental Medicine, Necmettin
Erbakan University.
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Experimental design
Rats were sacriﬁced by cervical dislocation and the descending thoracic aorta was quickly
isolated, cleaned, and sectioned into 3- to 4-mm-long rings. The aorta rings were mounted under
a resting tension of 1 g in a 15-ml organ bath ﬁlled with Krebs–Henseleit solution [composed of
(mM): NaCl 119, KCl 4.70, MgSO4 1.50, KH2PO4 1.20, CaCl2 2.50, NaHCO3 25, Glucose 11],
maintained at 37 °C, and aerated with 95% O2 and 5% CO2. Tissues were allowed to equilibrate
for 1 h. Changes in isometric tension of aortic rings were recorded using a four-channel force-
displacement transducer (BIOPAC MP36, Santa Barbara, CA, USA) connected through
ampliﬁers to a ITBS08 Integrated Tissue Bath System (Commat, Ankara, Turkey).
Adequate care was taken to insert the hooks without damaging the endothelium. After
the stabilization period, isometric contraction was induced by phenylephrine (10−6 M).
During the tonic phase of the contraction, acetylcholine (10−6 M) was added to verify the
integrity of the endothelium. The vascular endothelium was considered intact when the aortic
rings showed relaxation ≥50%, and non-functional if relaxation was ≤10%. After washing,
the tonic component of a second reaction was induced by phenylephrine (10−6 M) for 30 min,
followed by the cumulative addition of atorvastatin (10−10 to 3 × 10−4 M) to the organ baths
to induce relaxation.
After the ﬁrst concentration–response curve was completed, rings were washed and
allowed to reestablish resting tension. A second concentration–response curve to atorvastatin
(10−10 to 3 × 10−4 M) was determined in the presence of cilostazol (10−6 M). Cilostazol was
added to organ baths and the tissues were allowed to equilibrate for 30 min. Cilostazol and
atorvastatin were prepared daily.
The inﬂuence of nitric oxide on relaxations to atorvastatin was speciﬁcally addressed by
pretreating the rings with the nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester
(L-NAME, 10−4 M; 24). L-NAME had been added to the organ bath 20 min before
concentration–response curves were obtained.
Statistical analysis
Values are given as mean± SD. In all experiments, “n” is the number of rats from which the
aortas were obtained. Relaxation responses to atorvastatin were expressed as percentages of the
phenylephrine-induced contraction (10−6 M). The concentrations of atorvastatin causing 50%
of the maximal response (IC50) were calculated from each individual concentration–response
curves. pIC50 (−log IC50) values for atorvastatin (control and cilostazol-pretreated) curves
obtained were compared using Student’s t-test. Statistical signiﬁcance was set at p< 0.05.
Drugs
Phenylephrine, acetylcholine (dissolved in distilled water), cilostazol, and atorvastatin
[dissolved in dimethyl sulfoxide (DMSO)] were used. The concentration of DMSO in the
tissue bath was always kept below 0.4%. Phenylephrine and acetylcholine were obtained
from Sigma-Aldrich (St. Louis, MO, USA). Cilostazol and atorvastatin were kindly provided
by Abdi _Ibrahim Drug Industry (Istanbul, Turkey). DMSO was determined to have no effect
on phenylephrine-induced contractions.
Results
Atorvastatin (10−10 to 3 × 10−4 M) induced relaxation in a concentration-dependent way in
young and adult rat aortic rings precontracted with phenylephrine (Fig. 1). In young rat
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aortas, the relaxation response to atorvastatin was signiﬁcantly greater than in the aortas of
adult rats. The sensitivity of atorvastatin was signiﬁcantly decreased in mature rat aortas
(pIC50= 7.9± 0.1 in young and 5.6± 0.1 in adult rats, p< 0.05).
After incubation with the selective PDE3 inhibitor cilostazol (10−6 M), atorvastatin
evoked sustained relaxations of young and adult rat thoracic aorta rings in a concentration-
dependent manner. In the presence of cilostazol, atorvastatin induced relaxation in low
concentrations. Treatment with cilostazol signiﬁcantly enhanced the potency of atorvastatin
compared with control at both ages. Atorvastatin produced 80% relaxation at 10−10 M
concentration in the presence of cilostazol in both age groups.
Both in young and adult aortas, preincubation with the non-selective nitric oxide
synthase inhibitor L-NAME suppressed atorvastatin-induced relaxation (Figs 2 and 3).





















Fig. 1. Concentration–response curves showing
relaxations induced by atorvastatin (10−10 to 3× 10−4 M)
in young and adult rat thoracic aorta. Each point represents
the mean± SD expressed as a percentage of the tension
developed by 10−6 M phenylephrine. Each value is
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Fig. 2. Concentration–response
curves showing relaxations induced
by atorvastatin (10−10 to 3 × 10−4 M)
in young rat thoracic aorta, in the
presence of cilostazol (10−6 M) and
cilostazol (10−6 M) with L-NAME
(10−4 M). Each point represents the
mean± SD expressed as a percentage
of the tension developed by 10−6 M
phenylephrine. Each value is derived
from six experiments
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eliminate the relaxation to atorvastatin but signiﬁcantly reduced the potency of atorvastatin-
induced relaxation in both age groups. In L-NAME-preincubated rings, pIC50 values
decreased to 4.1± 0.6 in young and 4.9± 0.6 in adult rats (p< 0.05). Preincubation with
L-NAME in the presence of cilostazol diminished the vasodilator response to atorvastatin.
The maximal relaxations are 68%± 3.8 and 93%± 4.1 in young and adult rat aortas,
respectively.
On the other hand, we also determined that the concentration–response to atorvastatin
was reproducible (time-match control experiments) and did not change in the presence of the
vehicle of atorvastatin (DMSO), in terms of both maximum and pIC50 values (data not
shown).
Discussion
In this study, atorvastatin induced concentration-dependent relaxations in young and adult rat
thoracic aorta rings precontracted with phenylephrine. The sensitivity of atorvastatin was
signiﬁcantly decreased in adult rat aortas, and cilostazol pretreatment enhanced the potency
of atorvastatin. It has been reported that statins are also able to induce a vasodilation, which
may be endothelium-dependent and induced by an increased production of nitric oxide (2). It
is known that cilostazol and other cAMP-elevating agents increase nitric oxide production by
endothelial cells (24). In this study, we observed cilostazol potentiated atorvastatin-induced
relaxation for the ﬁrst time.
Beyond their primary mode of action of reducing plasma cholesterol levels, statins have
beneﬁcial effects on the cardiovascular system. Several studies have revealed that statins
enhance the bioavailability of nitric oxide and consequently improve endothelial function
(6, 7, 12, 18, 25, 31). We know that some factors, including age, inﬂuence the response of
vascular smooth muscle to exogenous agents. However, no previous in vitro data on the
effects of atorvastatin of rat thoracic aorta during aging or maturation have been published.
Zhang et al. (32) reported that atorvastatin can increase endothelial nitric oxide synthase
synthesis in the vital organs of aging rats, which partially explains the organ-protective effect






















curves showing relaxations induced
by atorvastatin (10−10 to 3 × 10−4 M)
in adult rat thoracic aorta, in the
presence of cilostazol (10−6 M) and
cilostazol (10−6 M) with L-NAME
(10−4 M). Each point represents the
mean± SD expressed as a percentage
of the tension developed by 10−6 M
phenylephrine. Each value is derived
from six experiments
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Our results indicate that atorvastatin induced concentration-dependent relaxation of
young and adult phenylephrine-contracted rat aortas. Phenylephrine, an alpha-adrenergic
agonist, contracts smooth muscle cells through the extracellular Ca2+ inﬂux in receptor-
operated Ca2+ channels and through the release of internal Ca2+ from speciﬁc inositol 1,4,
5-trisphosphate receptor channels in the sarcoplasmic reticulum membrane (13, 19). In this
study, atorvastatin inhibited the contraction induced by phenylephrine in a concentration-
dependent manner. This result suggests that atorvastatin can inhibit the vasocontraction
induced by extracellular Ca2+ entry via the receptor-operated Ca2+ channel pathway. Some
studies have demonstrated that simvastatin (1, 3, 27) and atorvastatin (27) also directly relax
vascular smooth muscle by inhibiting Ca2+ inﬂux through voltage-operated Ca2+ channels
and Ca2+ release from intracellular store site. Tesfamariam et al. (27) reported that
atorvastatin may have additional effects on Ca2+ regulation in vascular smooth muscle
that are not due to cholesterol depletion. They also observed that simvastatin and
atorvastatin may reduce agonist-stimulated rise in [Ca2+]i by inhibiting Ca
2+ inﬂux. It
is known that simvastatin and atorvastatin are lipophilic and freely diffuse into cells (11).
These ﬁndings support our results. Moreover, atorvastatin was more potent in the young
than in the adult group in this study. However, the mechanisms for the decreased sensitivity
to atorvastatin are unknown. Chronic and minor pathological changes of the vessel
morphology during aging might affect the potency of atorvastatin in rat aorta. To the
best of our knowledge, this is the ﬁrst in vitro study to show the effects of age on
atorvastatin-induced relaxations of isolated rat aorta. The maximal plasma concentration of
atorvastatin is reported to be 252 μM in patients treated with the recommended oral doses
(80 mg; 16). Thus, in this study, the lower concentrations of atorvastatin (10−10 to 3 ×
10−4 M), which initiate acute relaxant response in rat aorta, correspond to plasma levels of
this statin derived from commonly prescribed doses.
Cilostazol is an inhibitor of PDE3 that increases the levels of cAMP and the active form
of protein kinase A, a process closely related to the inhibition of platelet aggregation and
relaxation of vascular smooth muscle (15). In this study, we also investigated the role of
cilostazol pretreatment on the atorvastatin-induced responses. Interestingly, pretreatment
with cilostazol enhanced the potency of atorvastatin in both young and adult rat aortas.
Furthermore, in adult aortas, cilostazol enhanced the potency more potently than in the young
group. Based on our data, we cannot suggest which mechanisms underlie the increased
sensitivity to atorvastatin in the presence of cilostazol. Previously, we reported that
cumulative addition of cilostazol caused concentration-dependent relaxations of rat thoracic
aorta rings (23). However, no previous study has addressed the possible vascular interactions
of statins with cilostazol in isolated rat aorta. Cilostazol has many pharmacological actions,
including vasodilation, inhibition of platelet activation and aggregation, inhibition of
thrombosis, increased blood ﬂow to the limbs, improvement in serum lipids with lowering
of triglycerides and elevation of high-density lipoprotein cholesterol, and inhibition of growth
of vascular smooth muscle contractions (8, 14, 15). We know that statins are commonly used
by patients with cardiovascular diseases. Such patients frequently have cardiovascular
diseases, which may be treated with cilostazol. Nakamura et al. (21) have previously
reported the protein kinase A-independent vasodilating effect of PDE3 inhibition using
pressurized rabbit cerebral penetrating arterioles. It is expected that the effectiveness of
vasodilation by PDE3 inhibition is greatly dependent on the type of the blood vessel sampled,
the agonist stimulation, and the timing of drug treatment. Cilostazol is clinically applicable to
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the patients with intermittent claudication and atherosclerosis obliteration. It is generally
thought that endothelium-dependent vasodilation and capillary-like formation underlie the
protection of PDE3 inhibition against peripheral arterial disease. Nakamura et al. (22)
reported that cilostazol-induced vasodilation of the rat thoracic aorta was dependent on the
endothelium, which released nitric oxide from aortic endothelial cells. Furthermore, Li et al.
(17) reported that cilostazol induced the relaxation of rabbit thoracic aorta through activation
of the big-conductance Ca2+-activated K+ channel via an endothelium-independent, protein
kinase A-dependent signaling pathway. These investigators also suggested a cilostazol-
induced endothelium-independent relaxation, since the relaxations of cilostazol on endothe-
lium-intact and endothelium-denuded arteries were not different. In this study, incubation of
aortic rings with L-NAME in the presence of cilostazol did not completely eliminate the
relaxation to atorvastatin but signiﬁcantly reduced the responses of this statin in young and
adult rat aortas, especially in young rats. There appears to be a nitric oxide-independent effect
of atorvastatin since L-NAME did not totally abolish atorvastatin-induced relaxation.
Similarly, Sönmez Uydes¸-Dog˘an et al. (26) reported that pravastatin, atorvastatin, and
cerivastatin can acutely induce vasorelaxation on precontracted aortic rings via both
endothelium-dependent and -independent mechanisms. The Emax and IC50 values that the
researchers found were different from those of our work. The reason for this discrepancy may
be related to differences between contractile agents used, ages or sex of rats, and perhaps
working conditions. In that study, nitric oxide release seems to play a more dominant role in
atorvastatin responsiveness as determined by a higher inhibition of maximal relaxation by
nitric oxide synthase inhibitor NG-nitro-L-arginine (L-NOARG). Recently, Meschiari et al.
(20) reported that statins exert pleiotropic effects independent of cholesterol concentrations,
including upregulation of nitric oxide formation and matrix metalloproteinase (MMP)
downregulation. However, statins also increase tissue concentrations of nitrites, which
activate new signaling pathways independent of nitric oxide. Atorvastatin increased nitrite
concentrations and nitrite inhibited MMP-9 production by endothelial cells. Furthermore,
Guimarães et al. (10) reported that treatment with atorvastatin signiﬁcantly increased nitrite
concentrations in the aortas from hypertensive animals. But we have no explanation about
this part of the response because it is not possible to measure vascular nitrite concentrations in
our lab. Further studies should be carried out to clarify atorvastatin increasing nitrite
mechanisms.
In conclusion, combined drug therapy may be efﬁcacious in delaying the occurrence of
cardiovascular events. The results of Wang et al. (30) support our hypothesis that combined
treatment with atorvastatin + probucol+ cilostazol (APC) signiﬁcantly attenuates atheroscle-
rosis through inhibiting anti-inﬂammatory and antioxidant properties independent of the
lipid-lowering function. Although it remains to be veriﬁed clinically whether combined APC
treatment exhibits a “potent antiatherogenic function,” it seems that APC more strongly
attenuates the progression of atherosclerosis than statin alone in cholesterol-fed rabbits. The
investigators also reported that these insights may provide a new concept with which the
occurrence of cardiovascular events can be effectively delayed by APC-combined drug
treatment in the early stages in patients with or without established atherosclerotic cardio-
vascular disease. This ﬁnding is in line with ours. This study supports that the new concept of
statin–cilostazol combination could be valuable in cardiovascular prevention especially
during aging. In this study, we used only female rats; therefore, further studies must be
performed to clarify the gender difference.
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